Evidence map›Paper›PMID 35174322›Full record

ArticleJCSM rapid communications

Ageing contributes to phenotype transition in a mouse model of periodic paralysis.

Karen J Suetterlin, S Veronica Tan, Roope Mannikko, Rahul Phadke, Michael Orford, Simon Eaton, Avan A Sayer, Miranda D Grounds, Emma Matthews, Linda Greensmith and 1 more

Open access · goldAbstract read
In one paragraph

Article in JCSM rapid communications. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Karen J SuetterlinDepartment of Neuromuscular Diseases UCL Queen Square Institute of Neurology London UK.ORCID https://orcid.org/0000-0002-6505-9404
S Veronica TanMRC Centre for Neuromuscular Diseases UCL Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery London UK.ORCID https://orcid.org/0000-0002-6983-3081
Roope MannikkoDepartment of Neuromuscular Diseases UCL Queen Square Institute of Neurology London UK.ORCID https://orcid.org/0000-0002-8727-9184
Rahul PhadkeDepartment of Neuropathology Great Ormond Street Hospital London UK.ORCID https://orcid.org/0000-0001-9699-2718
Michael OrfordUCL Great Ormond Street Institute of Child Health London UK.
Simon EatonUCL Great Ormond Street Institute of Child Health London UK.ORCID https://orcid.org/0000-0003-0892-9204
Avan A SayerAGE Research Group, NIHR Newcastle Biomedical Research Centre Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University Newcastle upon Tyne UK.ORCID https://orcid.org/0000-0003-1283-6457
Miranda D GroundsSchool of Human Sciences University of Western Australia Perth Australia.ORCID https://orcid.org/0000-0002-4530-9402
Emma MatthewsDepartment of Neuromuscular Diseases UCL Queen Square Institute of Neurology London UK.ORCID https://orcid.org/0000-0002-3810-306X
Linda GreensmithDepartment of Neuromuscular Diseases UCL Queen Square Institute of Neurology London UK.ORCID https://orcid.org/0000-0002-7839-5052
Michael G HannaDepartment of Neuromuscular Diseases UCL Queen Square Institute of Neurology London UK.ORCID https://orcid.org/0000-0003-0825-4075
Great Ormond Street Hospital · GBNational Hospital for Neurology and Neurosurgery · GBNewcastle upon Tyne Hospitals NHS Foundation Trust · GBGuy's and St Thomas' NHS Foundation Trust · GBSt George’s University Hospitals NHS Foundation Trust · GBThe University of Western Australia · AU

Funding

Medical Research Council MR/M006948/1Medical Research Council MR/M01827X/1Wellcome Trust
6 · The paper itself

Abstract

backgroundPeriodic paralysis (PP) is a rare genetic disorder in which ion channel mutation causes episodic paralysis in association with hyper- or hypokalaemia. An unexplained but consistent feature of PP is that a phenotype transition occurs around the age of 40, in which the severity of potassium-induced muscle weakness declines but onset of fixed, progressive weakness is reported. This phenotype transition coincides with the age at which muscle mass and optimal motor function start to decline in healthy individuals. We sought to determine if the phenotype transition in PP is linked to the normal ageing phenotype transition and to explore the mechanisms involved.

methodsA mouse model of hyperkalaemic PP was compared with wild-type littermates across a range of ages (13-104 weeks). Only male mice were used as penetrance is incomplete in females. We adapted the muscle velocity recovery cycle technique from humans to examine murine muscle excitability

resultsBoth WT (

conclusionsThe phenotype transition with age is replicated in a mouse model of PP. Intrinsic muscle ageing protects against potassium-induced weakness in HyperPP mice. However, it also appears to accelerate impairment of sarcoplasmic reticulum calcium release, mitochondrial impairment and the development of core-like regions, suggesting acquired RyR1 dysfunction as the potential aetiology. This work provides a first description of mechanisms involved in phenotype transition with age in PP. It also demonstrates how studying phenotype transition with age in monogenic disease can yield novel insights into both disease physiology and the ageing process itself.

Indexed as

Ageing; Channelopathy; Periodic paralysis; Sarcopenia; Skeletal muscle; Ion channels

Identifiers

PMID35174322
PMCPMC8837191
OpenAlexW3157313351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.